SCHEMBL6877878

SCHEMBL6877878

CO/N=C/c1ccc(F)cc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.39
SRC P12931 1/20 0.34
KCNH2 Q12809 1/20 0.34
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
HCAR1 Q9BXC0 1/20 0.33
GRIN2D O15399 3/20 0.33
GRIN3B O60391 3/20 0.33
GRIN1 Q05586 3/20 0.33
GRIN2A Q12879 3/20 0.33
GRIN2B Q13224 3/20 0.33
GRIN2C Q14957 3/20 0.33
GRIN3A Q8TCU5 3/20 0.33
APP P05067 1/20 0.32
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ADORA2A P29274 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6877880 1.00 IDO1 (0.39) IDO1SRCKCNH2SLC6A2SLC6A4
SCHEMBL6077684 0.79 GRIN2D (0.51) SRCGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6077689 0.79 GRIN2D (0.51) SRCGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17712950 0.77 IDO1 (0.42) IDO1KCNH2HCAR1GRIN2DGRIN3B
SCHEMBL30292169 0.77 ALDH1A1 (0.40) IDO1KCNH2HCAR1GRIN2DGRIN3B
SCHEMBL17712949 0.77 IDO1 (0.42) IDO1KCNH2HCAR1GRIN2DGRIN3B
SCHEMBL5307396 0.77 ALDH1A1 (0.40) IDO1KCNH2HCAR1GRIN2DGRIN3B
SCHEMBL5307395 0.77 ALDH1A1 (0.40) IDO1KCNH2HCAR1GRIN2DGRIN3B
SCHEMBL3315926 0.76 IDO1 (0.43) IDO1KCNH2SLC6A2SLC6A4HCAR1
SCHEMBL6448341 0.76 MAPT (0.39) SRCGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6777440-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-08-17 US disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 IDO1 350/4885SRC 248/4885KCNH2 4319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.